PKU Financial Planning: Medicaid Preservation, Palynziq Costs, and SNT Strategy

Phenylketonuria (PKU) is the metabolic disorder where financial planning is inseparable from medical management. PKU requires a lifelong low-phenylalanine diet supplemented by specialized metabolic formula — and for those who qualify, FDA-approved medications that cost hundreds of thousands of dollars per year. The families and adults who manage PKU well medically often find themselves facing a parallel financial problem: formula costs that insurance refuses to cover, drugs that depend on Medicaid continuity, and an inheritance or job change that could quietly destroy the benefits structure keeping treatment accessible. This guide covers the specific financial planning steps that matter most for PKU families in 2026.

PKU spectrum and financial planning implications

PKU is caused by a deficiency of phenylalanine hydroxylase (PAH), the enzyme that converts the amino acid phenylalanine (phe) to tyrosine. Without adequate PAH activity, phe accumulates in the blood and brain, causing intellectual disability, seizures, and neurological damage if untreated. All 50 states screen for PKU at birth.¹

Approximately 13,000–16,000 Americans have PKU, with an incidence of roughly 1 in 10,000–15,000 live births.² Despite its relative rarity, PKU creates financial planning challenges that can reach $300,000 per year or more per patient when enzyme substitution therapy is involved.

Treatment costs: formula, sapropterin, and Palynziq

Metabolic formula — $8,000–$20,000/year, often uncovered

The foundation of PKU management is a phenylalanine-free or phe-restricted metabolic formula — a specialized amino acid supplement that replaces the protein the person cannot safely get from food. Adults with classic PKU typically require this formula for life. Without it, blood phe levels rise, cognitive function deteriorates, and neurological symptoms emerge.

The cost of metabolic formula is not trivial. Adult PKU patients spend $8,000–$20,000+ per year on formula and low-protein specialty foods, depending on formula type, body weight, phe tolerance, and state of residence.³ The financial problem is that most commercial health insurance plans have historically excluded "medical foods" from coverage — treating metabolic formula as a dietary product rather than a medical necessity, even though it is the primary treatment for the condition.

As of 2026, approximately 25 states have enacted laws requiring insurance coverage of PKU medical foods, but coverage mandates vary significantly in scope, dollar limits, and application to self-insured employer plans (which are ERISA-governed and generally exempt from state mandates).⁴ A family in a state without a mandate, or one covered by a self-insured employer plan, may face the full retail cost of formula out of pocket — while a family in California or Arkansas may have substantially better coverage. Medicaid, by contrast, typically covers metabolic formula as a medically necessary benefit in most states.

Sapropterin (Kuvan/generic) — more affordable since 2025

Sapropterin dihydrochloride (brand name Kuvan; BioMarin) is an oral tablet that treats BH4-responsive PKU — roughly 20–50% of PKU patients, predominantly those with mild-to-moderate disease. It reduces blood phe levels in responsive patients, allowing a less restrictive diet and reduced formula dependence. BioMarin's patent on Kuvan expired, and the first generic versions entered the US market in 2025, substantially reducing the cost compared to branded Kuvan. Patients who respond to sapropterin and can access affordable generics have significantly reduced financial exposure compared to those who require Palynziq.

Palynziq (pegvaliase) — enzyme substitution for classic PKU adults

Palynziq (pegvaliase-pqpz; BioMarin), approved by FDA in 2018, is a subcutaneous enzyme substitution therapy for adults with uncontrolled PKU. FDA expanded Palynziq's approval in March 2026 to adolescents ages 12 and older with blood phe levels above 600 µmol/L who do not respond adequately to sapropterin.⁵ It replaces the function of the deficient PAH enzyme and can dramatically reduce blood phe levels in patients who tolerate it, potentially allowing a much less restrictive diet.

Palynziq is one of the most expensive therapies in rare metabolic disease. Based on available pricing data, the annual list price is in the range of several hundred thousand dollars — with the actual per-patient cost varying by dose, which is titrated upward over the first year of treatment.⁶ BioMarin offers co-pay assistance programs that cap out-of-pocket costs for commercially insured patients. For uninsured or Medicaid patients, the access pathway is Medicaid prior authorization — which requires meeting clinical eligibility criteria and navigating a REMS program that certifies prescribers and patients.

SSI and SSDI eligibility for adults with PKU

Blue Book listing and functional evaluation

PKU is listed under SSA's Blue Book Section 10.00 (Endocrine Disorders), but a PKU diagnosis alone does not automatically qualify a person for SSI or SSDI benefits. SSA requires a showing that the condition results in functional limitations that prevent substantial gainful activity (SGA).⁷

PKU is not on SSA's Compassionate Allowances (CAL) list, which means there is no fast-track processing. Applications follow standard timelines — typically 3–6 months for an initial decision, with further appeals possible. The functional evaluation for PKU considers:

• Documented intellectual disability or cognitive impairment attributable to PKU (particularly from missed treatment in early childhood or periods of poor metabolic control)
• Neurological symptoms: seizure history (evaluated under Listing 11.02), movement disorders, or psychiatric symptoms (anxiety, ADHD, executive function deficits) documented by treating clinicians
• Inability to perform sedentary work, remembering and carrying out instructions, or maintaining attention and concentration

Adults with classic PKU who have been metabolically well-controlled from birth and have no cognitive impairment typically do not qualify for SSI or SSDI — they can work. The planning question for these adults is insurance continuity and state mandate access, not SSI. Adults with cognitive impairment from PKU, or those whose metabolic control has been poor, may qualify under functional criteria.

Children with PKU and SSI means-testing

A child with PKU whose parents have substantial income may qualify for Medicaid through a Medicaid waiver or state medical assistance program even without qualifying for SSI cash benefits. Many states have separate Medicaid programs for children with metabolic disorders that are not means-tested in the same way SSI is. A benefits counselor familiar with the family's state can identify all pathways to Medicaid coverage for formula and drug costs.

The 2024 food ISM rule change: a major shift for PKU families

Before September 30, 2024, SSA counted SNT-funded food and shelter payments as "In-Kind Support and Maintenance" (ISM) — reducing the SSI recipient's monthly payment by up to one-third of the Federal Benefit Rate ($994/month in 2026, so up to $331/month reduction).

This created a dilemma for PKU beneficiaries on SSI: metabolic formula is food, but it is also medically necessary treatment. Trustees had to choose between funding formula through the SNT (which reduced the SSI payment) or not funding it (which placed the cost burden on the family or the beneficiary's own income). Some families used workarounds — paying for formula through the beneficiary's own resources, or having the family pay directly rather than through the SNT — with significant administrative complexity.

Effective September 30, 2024, SSA eliminated ISM counting for food expenses entirely.⁸ A third-party SNT can now pay for a beneficiary's metabolic formula — and specialty low-protein foods — without any reduction in the SSI monthly payment. Shelter payments remain subject to ISM, but the food rule change directly removes the previous penalty for the most common SNT expense category for PKU beneficiaries.

Section 1619(b): Medicaid protection for working PKU adults

For a PKU adult who receives SSI and has begun working, Section 1619(b) of the Social Security Act is a critical protection. It allows a person on SSI to earn above the Substantial Gainful Activity level ($1,690/month in 2026) — and have their SSI cash payment reduced to zero by those earnings — while retaining full Medicaid coverage, as long as their annual earnings remain below their state's 1619(b) threshold.⁹

For a PKU adult who depends on Medicaid for access to Palynziq, Section 1619(b) is the financial boundary that determines whether taking a salary increase, accepting a promotion, or changing jobs is safe. Crossing the 1619(b) threshold terminates Medicaid — cutting off access to a drug that costs several hundred thousand dollars per year. Every working PKU adult on SSI should know their state's threshold, track their earnings against it, and have a plan modeled for what happens if their income approaches or exceeds it.

SNT strategy for PKU families

Third-party SNT: the core planning tool for parents

A parent who wants to leave assets to a child with classic PKU — especially one who relies on Medicaid for drug access — should fund a third-party Special Needs Trust rather than leaving assets directly. A direct inheritance, IRA beneficiary designation, or life insurance payout naming the beneficiary personally can immediately push their countable resources above the SSI limit ($2,000 for individuals), triggering loss of SSI and, in most states, automatic loss of Medicaid.

A properly-drafted third-party SNT is not a countable resource for SSI/Medicaid purposes. The trust can receive unlimited assets without affecting eligibility. Unlike first-party (self-settled) SNTs, a third-party SNT does not require a Medicaid payback provision on the beneficiary's death — remaining assets pass to whoever is named as the remainder beneficiary.

First-party (d4A) SNT: for personal injury settlements and direct inheritances

If a PKU beneficiary receives a personal injury settlement — or inadvertently receives a direct inheritance — a first-party SNT can shelter those funds from SSI/Medicaid resource counting, provided the trust is established before the funds are deposited in a personal account. For PKU-related injury settlements (such as malpractice for missed diagnosis or dietary supplement contamination), the first-party SNT must be established before the settlement check is issued. A Medicaid payback clause is required by federal law (42 U.S.C. § 1396p(d)(4)(A)).

PKU-specific SNT distribution language

Every SNT for a PKU beneficiary should include explicit language authorizing the following categories of expense, which are commonly questioned by institutional trustees without specific guidance:

• Metabolic formula and low-protein specialty foods — now unambiguously non-ISM as of September 2024 for food; vendor-direct payment is simple but no longer strictly required for SSI protection
• PKU management drugs — Palynziq, sapropterin/Kuvan, and any future enzyme therapies — as primary medical expenses
• Supplemental nutrition — tyrosine supplements, micronutrient formulations, and related amino acid supplements prescribed by the metabolic team
• Metabolic clinic costs — travel, lodging, and co-pays for regular blood phe monitoring, which is lifelong
• Dietary consultation and food preparation — registered dietitian specializing in PKU is a lifelong clinical need
• Mental health care — anxiety, ADHD, and executive function deficits are documented comorbidities of PKU, particularly in adults with periods of poor metabolic control
• Future gene therapy — a gene therapy program for PKU (Homology Medicines' HMI-102 and similar programs) may reach clinical use within the SNT's operative timeframe; a clause authorizing gene therapy-related costs preserves the trustee's authority to fund future treatments without a trust amendment

ABLE account for PKU adults

For a PKU adult who is working, the ABLE account is a practical tool to set aside funds for PKU-related expenses tax-free. Under IRC § 529A, ABLE account contributions of up to $20,000/year from third parties (the beneficiary's own contributions can be higher under ABLE-to-Work for employed ABLE account holders) can fund Qualified Disability Expenses, which include medical costs, treatment-related nutrition, and other disability-related expenses.¹⁰

PKU metabolic formula, drugs (Palynziq, sapropterin), dietitian fees, and metabolic clinic co-pays all qualify as medical or health-related Qualified Disability Expenses. For a working PKU adult who does not want or cannot establish an SNT, the ABLE account is the most accessible way to build a dedicated reserve for these expenses while maintaining SSI and Medicaid eligibility (ABLE balances up to $100,000 are excluded from SSI resource counting).

Effective January 2026, the ABLE Age Adjustment Act expanded ABLE account eligibility to individuals whose disability onset occurred before age 46 (previously before age 26). This change opens ABLE accounts to adults with PKU who were diagnosed at birth but did not open an ABLE account before their mid-twenties — removing a barrier that had limited ABLE access for this population.

Newborn screening planning steps

Because PKU is detected by universal newborn screening, financial planning can begin immediately after diagnosis — before any cognitive or developmental impact has occurred. The planning sequence for families receiving a newborn PKU diagnosis:

1. Verify insurance coverage for metabolic formula now. Call the insurance carrier and ask specifically whether formula and medical foods for phenylketonuria are covered. Ask for the coverage determination in writing. If the answer is no, research your state's PKU diet mandate law and whether your employer's plan is ERISA-governed (potentially outside state mandate scope).
2. Identify Medicaid as a backup. Even with strong commercial coverage, Medicaid enrollment provides a safety net for formula and future drug costs. A child with PKU in a state with a Medicaid buy-in program or CHIP coverage may be eligible regardless of parental income.
3. Update wills and beneficiary designations now. Any parent of a PKU child should review their will, life insurance beneficiary designations, and retirement account beneficiary forms. None of these should name the child directly if the child may rely on SSI/Medicaid as an adult. Consult an estate planning attorney about a third-party SNT funded by life insurance and testamentary transfer.
4. Open an ABLE account at age 18. If the child meets disability criteria, open an ABLE account at or after age 18 as a supplemental resource for PKU expenses during young adulthood and transition.
5. Apply for SSI at transition. At or before age 18, have a benefits counselor evaluate SSI eligibility. Many PKU adults with classic PKU and no cognitive impairment will not qualify for SSI cash benefits — but in states where Medicaid has a standalone program for PKU management, SSI eligibility is not the only path to Medicaid for adult medical foods and drug coverage.

The three professionals every PKU family needs

Managing PKU's financial and legal structure requires three distinct professionals working in coordination:

1. Metabolic team dietitian and physician — the clinical team documents blood phe levels, treatment history, functional limitations for SSI applications, and evolving treatment options. Their documentation drives both Medicaid prior authorization for Palynziq and SSI disability evaluations.
2. Special needs estate planning attorney — drafts the SNT, reviews beneficiary designations, integrates the trust with the parent's will and life insurance, and ensures the Medicaid payback clause (if first-party) complies with current SSA requirements.
3. Fee-only financial advisor specializing in special needs — models the lifetime cost of treatment (formula + drugs + clinic costs), projects the SNT funding needed to close the gap between benefits and actual expenses, coordinates ABLE account strategy with SSI limits, and plans the life insurance structure to fund the SNT at the parents' death.

Get matched with a special needs financial planning specialist

The financial planning questions for PKU families — formula cost coverage, Medicaid preservation for high-cost drug access, SNT structure, and benefits coordination — require an advisor with specific expertise. Our network includes fee-only financial advisors who specialize in special needs planning. Match for free, interview them yourself, and choose who you want to work with.

Sources

1. National PKU Alliance (NPKUA). About PKU: Newborn Screening. All 50 states and U.S. territories screen for PKU at birth.
2. National PKU Alliance (NPKUA). About PKU: Prevalence. PKU affects approximately 1 in 10,000–15,000 live births in the US.
3. van Wegberg AMJ, et al. "The financial and time burden associated with phenylketonuria treatment in the United States." Molecular Genetics and Metabolism Reports. 2019. PMC6807265. Average annual adult PKU formula costs reported at $7,753+ (2018 USD; adjusted for inflation in 2026 estimates).
4. HRSA Advisory Committee on Heritable Disorders in Newborns and Children. State Statutes and Regulations on Dietary Treatment for PKU. State mandate coverage patchwork; self-insured plans generally not subject to state mandates (ERISA preemption).
5. BioMarin Pharmaceutical. FDA Accepts BioMarin's Palynziq sNDA for Adolescents Ages 12–17. Priority review for expansion to adolescents; FDA approval decision expected and granted March 2026.
6. GoodRx Health. Palynziq Pricing. Retail and commercial insurance pricing data. BioMarin co-pay assistance caps patient cost at $18,200/year, indicating total annual therapy cost substantially exceeds this amount for insured patients.
7. SSA Blue Book. Adult Listings (Part A). Section 10.00: Endocrine Disorders, including phenylketonuria; diagnosis alone insufficient — functional limitation required.
8. SSA. What's New for 2026 — SSI Provisions. Elimination of food ISM effective September 30, 2024. Shelter payments remain subject to ISM; food payments (including medical foods) no longer reduce SSI.
9. SSA Disability Research. Continued Medicaid Eligibility (Section 1619(b)). 2026 state thresholds; Minnesota highest at $84,208/year. Allows SSI recipients with earnings above SGA to retain Medicaid as long as earnings remain below state threshold.
10. IRS. Publication 907: Tax Highlights for Persons with Disabilities. IRC § 529A ABLE account rules; 2026 annual contribution limit $20,000 (third-party), higher for ABLE-to-Work account holders; balances up to $100,000 excluded from SSI resource counting.

Values verified as of June 2026. PKU treatment pricing is subject to change; verify current costs with BioMarin patient access programs. 1619(b) thresholds updated annually by SSA. Consult a fee-only financial advisor and estate planning attorney before implementing any of the strategies described here.